TP 方案同期联合3DCRT 治疗局部晚期鼻咽癌的临床研究

目的：探讨TP方案（紫杉醇＋奈达铂）同期放化疗对局部晚期鼻咽癌的疗效及不良反应。方法：将60例Ⅲ期、ⅣA期的鼻咽癌患者分为TP 组（ n＝30）和PF（顺铂＋氟尿嘧啶）组（ n＝30）。两组化疗均从放疗的第1天开始，每3-4周化疗1次，两组均化疗2-3个周期。两组的放疗方法相同。分别观察并比较两组的近期疗效和不良反应。结果：TP 组和P F组的1年局部复发率、1年远处转移率、1年肿瘤相关死亡率、1年无疾病进展率分别为3．33％、3．33％、3．33％、96．33％和6．67％、3．33％、3．33％、90．00％，两组比较无显著性差异（ P＞0．05）。 TP 组和PF组在血液毒性及肝脏毒性方面无显著性差异（P＞0．05）；口腔粘膜反应及呕吐方面PF组较TP组显著增多（P＜0．05）。结论：TP 方案在疗效上与经典的P F方案相当，在减少不良反应方面TP方案有更好的优势。

The Clinical Study of Paclitaxel and Nedaplatin Chemotherapy Combined with Concurrent Radiotherapy in Treatment of Nasopharyngeal Carcinoma in Advanced Stage

Objective：To evaluate the efficacy and adverse reactions of paclitaxel and nedaplatin chem-otherapy in combination with concurrent radiotherapy for nasopharyngeal carcinoma of stage Ⅲ and IVa. Method：A total of 60 patients with advanced nasopharyngeal carcinoma were divided into group TP （ n=30） and group PF（n=30）.The two groups were treated with regimens every 3 weeks or 4 weeks as a cycle.The two groups of patients received two or three cycles .The chemotherapy of the two groups begin with the first day of radiotherapy .Both groups were given the same radiotherapy .and then evaluated the efficacy and adverse reactions of the two groups .Result： The 1-year recurrence from local regional failure survival rate , l-year distant metastasis rate , 1-year of tumor related mortality and 1-year free distant metastasis survival rate of group TP and group PF were respectively 3.33%, 3.33%, 3.33%, 96.33%and 6.67%, 3.33%, 3.33%,90. 00%.There was no difference between them in statistics （P〉0.05）.There was no differenc between the two groups in hematolgic toxicity and hepatotoxicity in statistics （ P〉0.05） .Group PF was worse than group TP in the oral mucosa reaction and vomiting （ P〈0.05） .Conclusion：There was no difference between TP and PF in the efficacy in statistics .TP was better than PF in the adverse reactions .